HSP60 predicts survival in advanced serous ovarian cancer

International Journal of Gynecological Cancer

Volumn 23, Issue 3, 2013, Pages 448-455

  Hjerpe, Elisabet ^a   Egyhazi, Suzanne ^b   Carlson, Joseph ^c   Stolt, Marianne Frostvik ^b   Schedvins, Kjell ^a   Johansson, Hemming ^a   Shoshan, Maria ^b   Åvall Lundqvist, Elisabeth ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c Departments of Pathology   (Sweden)

Author keywords

HSP60; Immunohistochemistry; Ovarian cancer; Real time PCR

Indexed keywords

CHAPERONIN 60; MESSENGER RNA; PLATINUM COMPLEX;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; ENDOMETRIOID CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; CHAPERONIN 60; CYSTADENOCARCINOMA, SEROUS; ENDOMETRIAL NEOPLASMS; FALLOPIAN TUBE NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; MITOCHONDRIAL PROTEINS; NEOPLASM GRADING; NEOPLASM STAGING; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDIES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE;

EID: 84876216378     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e318284308b     Document Type: Article

References (25)

1. Heintz APM, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary. Int J Gynecol Obstet. 2006;95:S161-S192.
2. Almeida MB, do Nascimento JLM, Herculano AM, et al. Molecular chaperones: Toward new therapeutic tools. Biomed Pharmacother. 2011;65:239-243.
3. Guttmann DM, Koumenis C. The heat shock proteins as targets for radiosensitization and chemosensitization in cancer. Cancer Biol Ther. 2011;12:1023-1031.
4. Beere HM. Death versus survival: Functional interaction between the apoptotic and stress-inducible heat shock protein pathways. J Clin Investig. 2005;115:2633-2639.
5. Cappello F, Czarnecka AM, La Rocca G, et al. HSP60 and HSP10 as antitumour molecular agents. Cancer Biol Ther. 2007;6:487-489.
6. Ghosh JC, Dohi T, Kang BH, et al. HSP60 regulation of tumor cell apoptosis. J Biol Chem. 2008;283:5188-5194.
7. Ghosh JC, Siegelin MD, Dohi T, et al. Heat shock protein 60 regulation of the mitochondrial permeability transition pore in tumor cells. Cancer Research. 2010;70:8988-8993.
8. Cappello F, Conway de Macario E, Marasa L, et al. HSP60 expression, new locations, functions, and perspectives for cancer diagnosis and therapy. Cancer Biol Ther. 2008;7:801-809.
9. Arya R, Mallik M, Lakhotia SC. Heat shock genesVintegrating cell survival and death. J Biosci. 2007;32:595-610.
10. Chandra D, Choy G, Tang DG. Cytosolic accumulation of HSP60 during apoptosis with or without apparent mitochondrial release. J Biol Chem. 2007;282:31289-31301.
11. Chun JN, Choi B, LeeKW, et al. Cytosolic HSP60 is involved in the NF-JBYdependent survival of cancer cells via IKK regulation. PLoS ONE. 2010;5:e9422.
12. Chaiwatanasirikul KA, Sala A. The tumour-suppressive function of CLU is explained by its localisation and interaction with HSP60. Cell Death Dis. 2011;2:e219.
13. Tsai Y-P, Yang M-H, Huang C-H, et al. Interaction between HSP60 and A-catenin promotes metastasis. Carcinogenesis. 2009;30:1049-1057.
14. Ciocca DR, Calderwood SK. Heat shock proteins in cancer: Diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones. 2005;10:86-103.
15. Cohen M, Dromard M, Petignat P. Heat shock proteins in ovarian cancer: A potential target for therapy. Gynecol Oncol. 2010;119:164-166.
16. Castilla C, Congregado B, Conde JM, et al. Immunohistochemical expression of HSP60 correlates with tumor progression and hormone resistance in prostate cancer. Urology. 2010;76:1017.e1-1017.e6.
17. Glaessgen A, Jonmarker S, Lindberg A, et al. Heat shock proteins 27, 60 and 70 as prognostic markers of prostate cancer. APMIS. 2008;116:888-895.
18. Xu X,WangW, ShaoW, et al. Heat shock protein-60 expression was significantly correlated with the prognosis of lung adenocarcinoma. J Surg Oncol. 2011;104:598-603.
19. Kimura E, Enns RE, Alcaraz JE, et al. Correlation of the survival of ovarian cancer patients with mRNA expression of the 60-kD heat-shock protein HSP60. J Clin Oncol. 1993;11:891-898.
20. Schneider J, Jiménez E, Marenbach K, et al. Immunohistochemical detection of HSP60-expression in human ovarian cancer. Correlations with survival in a series of 247 patients. Anticancer Res. 1999;19:2141-2146.
21. Tavassoe'li F, Devilee P. World Health Organization Classification of Tumours. In: Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon, France: IARC Press; 2003.
22. Rustin GJS. Use of CA-125 to assess response to new agents in ovarian cancer trials. J of Clin Oncol. 2003;21:187-193.
23. Rustin GJS. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer. 2011;21:419-423.
24. Bjorge L, Hakulinen J, Vintermyr OK, et al. Ascitic complement system in ovarian cancer. Br J Cancer. 2005;92:895-905.
25. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.